Price Cuts For Daewoong As Korea Attacks Rebates
This article was originally published in PharmAsia News
Executive Summary
South Korea's Ministry of Health and Welfare will cut the prices of five products from Daewoong Pharmaceutical by 20% from May following a Seoul court's ruling last year that found the pharma firm guilty of providing illegal rebates in return for prescriptions.
You may also be interested in...
Korea Revises Rules To Curb Rebate Activities, Improve Ethics
South Korea continues efforts to root out illegal rebate payments for drugs and to step up the pharma industry's ethics and social responsibility by revising relevant rules, but in a way that doesn't harm patients' health.
Dong-A Faces Price Hit As Korea Ups Fight Against Illegal Rebates
In its ongoing clamp down against illegal rebate activities in the domestic pharmaceutical industry, South Korea cuts prices of Dong-A ST’s drugs. This follows recent punitive measures against Novartis' Korean subsidiary.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.